Cystinuria Treatment Market to Witness Widespread Expansion by 2030

Cystinuria is a rare autosomal recessive metabolic disease causing defective transepithelial amino acid transport in the kidneys. Cystine dissolves and returns to the bloodstream after entering the kidneys. People with cystinuria have a genetic defect that interferes with this process. As a result, cystine builds up in urine and forms crystals or stones.

High demand for disease specific novel treatment is a major driver of the global cystinuria treatment market. Cystinuria is rare disease; however, pharmaceutical companies are continuously innovating new treatment methods and drug class for cystinuria treatment. In July 2019, Retrophin announced the FDA approval of THIOLA EC (tiopronin) 100mg and 300mg tablets for the treatment of cystinuria.
However, limited funding and operating revenue for research & development on targeted therapies for cystinuria hamper the growth of the global market

In terms of drug treatment, the global cystinuria treatment market can be classified into captopril, tiopronin, penicillamine, and others
Penicillamine is the first-generation chelating agent, which mixes with cystine to form a soluble disulfide complex, thereby preventing stone formation and possibly even dissolving existing cystine stones. In May 2019, Amerigen Pharmaceuticals Limited received the U.S. FDA approval for Penicillamine Capsules USP 250 mg.

Request a Sample to Get Extensive Insights into the Cystinuria Treatment Market

Based on distribution channel, the global cystinuria treatment market can be divided into hospital pharmacies, retail pharmacies, and online pharmacies
The retail pharmacies segment accounted for the largest share of the global cystinuria treatment market in 2019. However, the online pharmacies segment is expected to grow at a rapid pace from 2020 to 2030.
Increase in popularity of online pharmacies for obtaining prescribed drugs and steady adoption of this distribution channel by customers are factors fueling the growth of the segment

In terms of region, the global cystinuria treatment market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
In terms of revenue, North America dominated the global cystinuria treatment market in 2019, followed by Europe. However, the market in Asia Pacific is likely to expand at a higher CAGR from 2020 to 2030.
Rise in cases of cystinuria, surge in use & awareness about cystinuria treatments and procedures, and technological advancements are the key factors boosting the growth of the cystinuria treatment market in North America
Cystinuria affects about 1 in 15,000 people in the U.S. Heterozygote carriers are about 1 in 170 people. It accounts for approximately 1% of all renal stones.

Looking for Customized Insights to build your Business for Future, Ask for a Custom Report here